Fair Value Calculator Fair Value Calculator
EN DE

INDOBORAX (INDOBORAX) Fair Value & Analysis

Basic Materials · Market cap ₹12.6B

I INDOBORAX INDOBORAX · NSE
Price₹391.60
Fair Value₹182.77
Upside-53.3%
Quality75/100
Watch INDOBORAX for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹138.05 – ₹366.67

Fair value as of: Jul 3, 2026

From 26 valuation models · updated today

Share price +13.2% over the past month.

Price vs Fair Value (12 months)

₹391.60 ₹216.49 Fair Value ₹182.77 Jul 2025 Jul 2026

12‑month range ₹216.49 – ₹391.60 · fair‑value band ₹138.05 – ₹366.67 · the ₹391.60 price screens above the ₹182.77 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

INDOBORAX (INDOBORAX) currently trades at ₹391.60, while our model-based Fair Value estimate is ₹182.77 — implying the stock looks roughly 53.3% overvalued today. We read business quality at 75/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, INDOBORAX generated revenue of ₹2.2B at a net margin of 23.3%. Revenue grew 20.4% year over year. It earns a return on equity of 13.9%. The balance sheet holds a net cash position of ₹125M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) ₹2.2B
Revenue growth (YoY) +20.4%
Net margin 23.3%
Return on equity 13.9%
Free cash flow ₹955M FY2026
P/E ratio 25.0
More key figures
Operating margin 19.3%
EPS (TTM) ₹15.66
Dividend yield 2.7%
EPS growth (YoY) +42.0%
Net cash ₹125M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

INDOBORAX reported revenue of ₹2.2B in FY2026 versus ₹1.8B in FY2022, a compound +5.2%/yr. Reported net income was ₹503M in FY2026, compounding +8.4%/yr from FY2022.

Revenue +5.2%/yr
FY22 ₹1.8B
FY23 ₹2.3B
FY24 ₹1.9B
FY25 ₹1.8B
FY26 ₹2.2B
Net income +8.4%/yr
FY22 ₹364M
FY23 ₹507M
FY24 ₹390M
FY25 ₹425M
FY26 ₹503M

Is INDOBORAX fairly valued? → Check now

Similar stocks

6 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
Linde plc LIN €443.00 €109.98 -75%
Shin-Etsu Chemical Co SHECY $22.77 $13.22 -42%
BASF SE BAS €49.17 €23.76 -52%
Ningxia Baofeng Energy Group 600989 ¥22.46 ¥37.07 +65%
Dow Inc D1OW34 R$43.92 R$86.14 +96%
Ganfeng Lithium Group 002460 ¥72.05 ¥21.69 -70%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is INDOBORAX (INDOBORAX) undervalued?
As of Jul 3, 2026, our model estimates a fair value of ₹182.77 versus a price of ₹391.60 — about −53% (overvalued). Model-based estimate, not financial advice.
What is the fair value of INDOBORAX?
Our model-based fair value for INDOBORAX is ₹182.77 (as of Jul 3, 2026), built from audited fundamentals. The current price is ₹391.60.
What is the quality score of INDOBORAX?
INDOBORAX has a Quality Score of 75/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of INDOBORAX (INDOBORAX)?
INDOBORAX reported trailing-twelve-month revenue of about ₹2.2B (latest available figure, as of Jul 3, 2026).
What is the net profit margin of INDOBORAX?
The net profit margin of INDOBORAX is about 23.3%, meaning it keeps roughly 23.3% of revenue as net income. Based on the latest reported figures.
Does INDOBORAX pay a dividend?
INDOBORAX currently shows a dividend yield of about 2.66% relative to its recent price (as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.